The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Incidence of second primary malignancies (SPM) after 6-years follow-up of continuous lenalidomide in first-line treatment of multiple myeloma (MM).
A. C. Rossi
No relevant relationships to disclose
T. M. Mark
Consultant or Advisory Role - Celgene
Honoraria - Celgene; Millennium
Research Funding - Celgene
D. Jayabalan
No relevant relationships to disclose
P. J. Christos
No relevant relationships to disclose
F. Zafar
No relevant relationships to disclose
K. Pekle
No relevant relationships to disclose
T. Shore
No relevant relationships to disclose
R. N. Pearse
No relevant relationships to disclose
J. Leonard
No relevant relationships to disclose
S. Chen-Kiang
No relevant relationships to disclose
M. Coleman
No relevant relationships to disclose
R. Niesvizky
Consultant or Advisory Role - Celgene; Millennium; Onyx
Honoraria - Celgene; Millennium
Research Funding - Celgene; Millennium; Onyx